Company Focus
argenx
Latest argenx News
Biotechnology
UCB has presented new long-term data for Rystiggo (rozanolixizumab) and Zilbrysq (zilucoplan), underlining its ambition to build a broader position in generalized myasthenia gravis, a rare autoimmune neuromuscular disease where targeted therapies are reshaping treatment. 8 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing atacicept and other targeted therapies for serious immunological and kidney diseases with high unmet medical need.
Latest News & Features of interest to argenx
Biotechnology
UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the Bank says is its largest direct investment in a life sciences company. 9 July 2026
Pharmaceutical
German family-owned drugmaker Grünenthal today announced that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). 8 July 2026
Biotechnology
The US Food and Drug Administration (FDA) has granted US biotech Vera Therapeutics’ Trutakna (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgAN at risk for disease progression. 8 July 2026
Biotechnology
UCB has presented new long-term data for Rystiggo (rozanolixizumab) and Zilbrysq (zilucoplan), underlining its ambition to build a broader position in generalized myasthenia gravis, a rare autoimmune neuromuscular disease where targeted therapies are reshaping treatment. 8 July 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Pharmaceutical
Florida, USA-based clinical-stage biopharma DemeRx has appointed Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from pre-clinical research through clinical development. 8 July 2026
Pharmaceutical
Italian drugmaker Italfarmaco has presented new clinical data supporting the long-term use of Duvyzat (givinostat) in Duchenne muscular dystrophy (DMD), including MRI findings suggesting the therapy may help preserve muscle tissue and reduce fat infiltration. 7 July 2026
Biotechnology
The European Commission has approved Danish biotech Genmab and US pharma major AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, widening the bispecific antibody’s European label into an earlier treatment setting 7 July 2026
Biotechnology
UK biotech Compass Pathways today announced the 26-week results (Part B) from its second ongoing Phase III COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. 7 July 2026
Pharmaceutical
US drug developer Crinetics Pharmaceuticals saw its shares rocket 99% to $83.64 in pre-market activity today, following the news of a takeover bid from Vertex Pharmaceuticals. 7 July 2026
Latest In Brief for argenx
Biotechnology
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy privately held blood disorder drug developer Star Therapeutics amid a wave of acquisitions by midsized drugmakers looking to supplement their pipelines, according to a Financial Times report. 8 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze